Financial Performance - The company's revenue for Q1 2025 was CNY 137,160,578.06, representing a year-over-year increase of 20.02% compared to CNY 114,282,281.78 in the same period last year[4]. - The net loss attributable to shareholders for the period was CNY 11,545,431.51, a significant improvement from a loss of CNY 170,095,866.61 in the previous year[4]. - Total operating revenue for Q1 2025 was ¥137,160,578.06, an increase of 20.00% compared to ¥114,282,281.78 in Q1 2024[18]. - Net profit for Q1 2025 was a loss of ¥11,545,431.51, an improvement from a loss of ¥174,882,984.28 in Q1 2024[19]. - The total comprehensive loss for Q1 2025 was ¥11,549,283.95, an improvement from a loss of ¥174,560,182.55 in Q1 2024[19]. Cash Flow - The net cash flow from operating activities was a net outflow of CNY 13,801,882.53, which is an improvement of CNY 94,393,791.82 compared to the previous year's outflow[7]. - Cash flow from operating activities showed a net outflow of ¥13,801,882.53 in Q1 2025, compared to a net outflow of ¥108,195,674.35 in Q1 2024[21]. - Cash flow from investing activities resulted in a net outflow of ¥437,359,085.65 in Q1 2025, contrasting with a net inflow of ¥275,011,228.44 in Q1 2024[22]. - Cash and cash equivalents at the end of Q1 2025 were ¥1,055,668,836.98, down from ¥2,374,907,374.57 at the end of Q1 2024[22]. Research and Development - Research and development (R&D) expenses totaled CNY 88,924,234.66, a decrease of 28.48% from CNY 124,328,450.39 in the same period last year, with R&D expenses accounting for 64.83% of revenue, down 43.96 percentage points[4][7]. - Research and development expenses were ¥72,712,590.56 in Q1 2025, down 25.00% from ¥96,745,611.33 in Q1 2024[18]. - The company continues to focus on enhancing R&D efficiency and integrating resources across different pipelines to drive future growth[7]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 7,820,387,409.65, a decrease of 1.73% from CNY 7,958,132,235.38 at the end of the previous year[5]. - The company's current assets totaled CNY 4,134,286,329.53, down from CNY 4,282,490,715.65, indicating a decrease of about 3.45%[13]. - The company's total liabilities were CNY 2,921,615,159.54, down from CNY 3,048,260,581.65, showing a reduction of around 4.17%[15]. - The total equity attributable to the owners of the parent company was CNY 4,898,772,250.11, slightly decreasing from CNY 4,909,871,653.73, a change of about 0.23%[15]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 17,828[9]. - The company has not reported any significant changes in its major shareholders or their participation in margin trading activities[11]. Profitability Metrics - The weighted average return on equity improved by 3.04 percentage points to -0.24% from -3.28% in the previous year[4]. - The company's gross profit margin improved by 23.14 percentage points due to optimized production capacity and cost control measures[7]. - The company's inventory increased to CNY 322,559,055.80 from CNY 283,414,610.09, marking an increase of approximately 13.80%[13]. - The company's short-term borrowings decreased to CNY 213,622,195.45 from CNY 377,348,417.32, a reduction of about 43.45%[15]. - The company's long-term borrowings increased to CNY 1,114,926,712.74 from CNY 1,098,538,320.81, reflecting an increase of approximately 1.49%[15].

Revenue and Profitability - The company's revenue for the first quarter reached RMB 137,160,578.06, representing a year-on-year increase of 20.02% compared to RMB 114,282,281.78[6]. - The net loss attributable to shareholders for the quarter was RMB 11,545,431.51, a significant improvement from a loss of RMB 170,095,866.61 in the same period last year, narrowing the loss by 88.41%[14][15]. - The gross profit margin improved by 23.14 percentage points due to optimized production capacity and cost reduction measures[16]. - The basic and diluted earnings per share for the quarter were both RMB (0.05), compared to RMB (0.69) in the same period last year[6]. - The company confirmed a net loss attributable to shareholders after excluding non-recurring gains and losses of RMB 55,234,681.60, compared to RMB 178,676,681.71 in the previous year[6][15]. - In Q1 2025, the company reported a total comprehensive loss of CNY 11,549,283.95, compared to a loss of CNY 169,773,064.88 in Q1 2024, indicating a significant improvement[32]. Research and Development - Research and development expenses totaled RMB 88,924,234.66, a decrease of 28.48% from RMB 124,328,450.39 in the previous year, with R&D expenses accounting for 64.83% of revenue[8]. - The proportion of R&D investment to operating income decreased by 43.96 percentage points, while total R&D investment decreased by 28.48% year-on-year, despite a 20.02% increase in operating income, indicating improved R&D efficiency[17]. - The company is focusing on integrating R&D resources and enhancing potential synergies across different pipelines to control R&D expenditures effectively[17]. Cash Flow and Financial Management - The company reported a net cash flow from operating activities of RMB (13,801,882.53), compared to RMB (108,195,674.35) in the previous year, indicating improved cash flow management[6]. - The net cash flow from operating activities for the reporting period was a net outflow of ¥13,801,882.53, a decrease of ¥94,393,791.82 compared to the same period last year, with operating cash inflow increasing by ¥59,603,047.08 due to higher sales revenue and collections of the brand Manhaixin®[17]. - Cash inflow from operating activities increased to CNY 235,251,379.47 in Q1 2025, up from CNY 175,648,332.39 in Q1 2024, reflecting a growth of approximately 34%[34]. - The company recorded cash outflow from investing activities of CNY 437,359,085.65 in Q1 2025, compared to an inflow of CNY 275,011,228.44 in Q1 2024, indicating a shift in investment strategy[36]. - The company incurred total cash outflows from financing activities of CNY 334,582,241.70 in Q1 2025, compared to CNY 168,104,615.34 in Q1 2024, indicating increased financing activities[36]. Assets and Liabilities - The total assets at the end of the reporting period were RMB 7,820,387,409.65, a decrease of 1.73% from RMB 7,958,132,235.38 at the end of the previous year[8]. - Total liabilities as of March 31, 2025, were RMB 2,921,615,159.54, down from RMB 3,048,260,581.65 as of December 31, 2024[26]. - Total equity attributable to shareholders as of March 31, 2025, was RMB 4,898,772,250.11, slightly down from RMB 4,909,871,653.73 as of December 31, 2024[26]. - The company reported other income of RMB 45,863,689.09 in Q1 2025, a significant increase from RMB 8,591,840.84 in Q1 2024[30]. Shareholder Information - The top ten shareholders held a total of 39.55% of shares, with HKSCC NOMINEES LIMITED being the largest shareholder with 97,857,297 shares[19]. - The company has not reported any changes in the participation of major shareholders in securities lending activities during the reporting period[21].

Financial Performance - The company reported a basic earnings per share of -0.0500 yuan for Q1 2025, a significant improvement of 92.75% compared to -0.6900 yuan in Q1 2024 [1] - Revenue for Q1 2025 was 1.37 billion yuan, representing a 20.18% increase from 1.14 billion yuan in Q1 2024 [1] - The net profit for Q1 2025 was -0.12 billion yuan, showing a 92.94% improvement from -1.7 billion yuan in Q1 2024 [1] - The return on equity for Q1 2025 was -0.24%, a notable improvement from -3.28% in Q1 2024 [1] Shareholder Information - The top ten unrestricted shareholders collectively hold 17,638.31 million shares, accounting for 71.28% of the circulating shares, with a decrease of 81.52 million shares compared to the previous period [2] - HKSCC NOMINEES LIMITED remains the largest shareholder with 9,785.73 million shares, representing 39.55% of the total share capital [3] - The advanced manufacturing industry investment fund (limited partnership) saw a decrease of 81.52 million shares [3] Dividend Distribution - The company has announced that there will be no distribution or transfer of dividends this time [4]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●会议召开时间：2025年4月30日（星期三）16:00-17:00 ●会议召开地点：上海证券交易所上证路演中心 （一）会议召开时间：2025年4月30日（星期三）16:00-17:00 （二）会议召开地点：上证路演中心 （三）会议召开方式：上证路演中心网络互动 三、 参加人员 （网址：http://roadshow.sseinfo.com） ●会议召开方式：上证路演中心网络互动 ●投资者可于2025年4月23日（星期三）至4月29日（星期二）16:00前登录上证路演中心网站首页点 击"提问预征集"栏目或通过公司投资者关系邮箱（ir@cansinotech.com）进行提问。公司将在说明会上 对投资者普遍关注的问题进行回答。 康希诺生物股份公司（以下简称"公司"）已于2025年3月26日发布2024年年度报告，并将于2025年4月30 日发布2025年第一季度报告。为便于广大投资者更全面深入地了解公司经营成果 ...

Financial Performance - Total revenue for 2024 reached RMB 824.884 million, a significant increase from RMB 345.182 million in 2023, representing a growth of 139.2%[7] - The company reported an operating loss of RMB 403.39 million for 2024, an improvement compared to the operating loss of RMB 2.035 billion in 2023[7] - The company reported a gross profit of approximately RMB 580.5 million, recovering from a gross loss of RMB 876.0 million in 2023[63] - Revenue from the cerebrospinal meningitis vaccine product reached RMB 793.8 million in 2024, up from RMB 561.7 million in 2023[60] - Other income decreased by 44.5% to approximately RMB 109.5 million in 2024, primarily due to a reduction in government subsidies[64] - Financial income decreased from approximately RMB 563 million for the year ended December 31, 2023, to approximately RMB 222 million for the year ended December 31, 2024, primarily due to a reduction in financial income of approximately RMB 362 million[70] - Income tax expense for the year ended December 31, 2024, was approximately RMB 25 million, a decrease from approximately RMB 115 million in 2023, due to the write-off of deferred tax assets[71] Assets and Liabilities - Total assets decreased to RMB 7.958 billion in 2024 from RMB 9.319 billion in 2023, a decline of 14.6%[7] - The company’s total liabilities decreased to RMB 3.048 billion in 2024 from RMB 4.031 billion in 2023, a reduction of 24.4%[7] - The company’s total equity decreased to RMB 4.910 billion in 2024 from RMB 5.287 billion in 2023, a decline of 7.1%[7] - Non-current assets were reported at RMB 3.676 billion in 2024, down from RMB 4.138 billion in 2023, indicating a decrease of 11.1%[7] - Cash and cash equivalents decreased by 24% from approximately RMB 20,470 million as of December 31, 2023, to approximately RMB 15,565 million as of December 31, 2024, mainly due to cash outflows from operating activities and loan repayments[87] - Total current liabilities decreased from approximately RMB 25,918 million as of December 31, 2023, to approximately RMB 17,720 million as of December 31, 2024, reflecting a reduction in borrowings and other payables[87] Vaccine Development and Commercialization - The sales revenue from the four-valent meningococcal conjugate vaccine, Manhaixin®, and the bivalent meningococcal conjugate vaccine, Meinaixi®, amounted to approximately RMB 793.8 million in 2024, reflecting a year-on-year growth of 41.3%[9] - The company plans to expand the age range for the Manhaixin® vaccine from children aged 3 months to 3 years to those aged 3 months to 6 years, pending regulatory approval[9] - The company is set to launch a new product, a 13-valent pneumonia combined vaccine, in 2025, with the registration application already accepted in 2024[10] - The company has initiated Phase II/III clinical trials for a component DTP vaccine for adolescents and adults, and the registration application for the infant DTP vaccine has been accepted and prioritized for review[10] - The company has received over $19 million in funding for the development of a recombinant poliovirus vaccine, highlighting its role in improving global public health[12] - The company has obtained product registration for its vaccine in Indonesia and is conducting clinical trials for safety and immunogenicity in the 18-55 age group[13] - The company is collaborating with the National Institute of Biotechnology Malaysia to advance the development of an mRNA polyvalent influenza vaccine[13] - The company aims to establish long-term strategic partnerships based on its diverse product pipeline and is preparing for WHO prequalification to explore international procurement opportunities[14] - The company has transformed from a biotechnology company to a biopharmaceutical company, enhancing its self-sustaining capabilities as more products enter commercialization[14] - The company has a broad vaccine portfolio addressing over ten disease areas, with five commercialized products as of the report date[18] Research and Development - The company has improved the production technology of the investigational PCV13i vaccine, achieving good safety and immunogenicity in its Phase III clinical trial[29] - The company has received GMP certification for its Ad5-EBOV vaccine, which is the first Ebola vaccine approved in China for emergency use[28] - The company is advancing its pipeline of innovative vaccines, including mRNA-based influenza vaccines and other combination vaccines[20] - The company's new drug application for PCV13i has been accepted by the National Medical Products Administration, with expectations to obtain approval by 2025[30] - The PBPV vaccine, currently in Phase I clinical trials, shows good safety in adults and the elderly, with significant antibody responses observed[32] - The infant DTcP vaccine's new drug application has been accepted, with ongoing Phase III clinical trials and a summary report already obtained[35] - The tetanus vaccine has initiated Phase III clinical trials, with a new drug application expected to be approved in the first half of 2026[40] - The company has secured exclusive global rights from McMaster University for the development of a tuberculosis booster vaccine, with promising results from Phase I trials[41] - The PBPV vaccine aims to provide broader coverage than existing PPV23 and PCV13 products, targeting over 90 serotypes of pneumonia[31] - The company plans to strengthen clinical data for the infant DTcP vaccine in 2025 to expedite the review process[35] Corporate Governance - The company emphasizes the importance of independent judgment and oversight from its board members, enhancing corporate governance standards[106][107][108] - The board comprises members with diverse backgrounds in finance, healthcare, and management, contributing to a well-rounded decision-making process[109][110] - The company is focused on maintaining high standards of corporate governance through experienced independent directors and supervisors[112] - The company has adopted all applicable provisions of the corporate governance code as per the Hong Kong Listing Rules Appendix C1[120] - The company confirmed that all directors and supervisors complied with the standard code during the reporting period[121] - The company has established specific service contracts for all directors, with terms lasting until the current board's three-year term expires[133] - The nomination committee will identify suitable candidates to fill any board vacancies based on required skills and experience[134] - The company will continue to assess whether the roles of chairman and CEO should be separated in the future[129] - The company has maintained compliance with the requirement of having at least three independent non-executive directors on the board[130] - The board of directors is responsible for leading and monitoring the company, ensuring effective internal controls and risk management systems[136] Market Strategy and Expansion - The company plans to enhance its marketing efforts and strengthen professional academic promotion to increase public awareness of vaccines[57] - The company aims to expand its market presence in Southeast Asia, the Middle East, and Latin America through strategic acquisitions and partnerships[58] - The company is actively expanding its commercialization efforts, focusing on key clinical decision-makers and vaccination points to enhance market presence[55] - The company has a robust strategy for market expansion and product development in the biopharmaceutical sector[102] - The company is committed to providing high-quality, innovative, and accessible vaccines globally as part of its mission[183] Human Resources and Corporate Culture - The company has established a training program for new employees to enhance understanding of corporate culture and compliance[184] - The company aims to maintain a gender ratio among employees, with male employees accounting for 48.6% and female employees accounting for 51.4%[165] - The board currently consists of 7 members, including 3 executive directors, 1 non-executive director, and 3 independent non-executive directors, with 1 female director and 6 male directors[163] - The company is committed to achieving gender equality on the board as a long-term goal[164] - The company has established a whistleblowing policy that encourages reporting of misconduct, ensuring confidentiality and protection for whistleblowers[170] - The company emphasizes a corporate culture focused on innovation, quality, and responsibility, with a vision of "Innovation without end, a world without epidemics"[183]

Key Points Summary of 康希诺生物 Conference Call Company Overview - 康希诺生物 (CanSino Biologics) is a biotechnology company focused on vaccine development and commercialization, particularly in the fields of infectious diseases. Financial Performance - In 2024, 康希诺's revenue exceeded 846 million yuan, representing a year-on-year growth of 137% [3] - Vaccine business revenue surpassed 800 million yuan, growing over 40% compared to the previous year [3] - The company's annual loss significantly narrowed by over 74%, with a net loss close to 80% after excluding one-time investment losses [3] - The three expense ratios (R&D, sales, and management) decreased significantly year-on-year, indicating effective cost control measures [3] Product Development and Market Position - 康希诺's four-valent meningococcal conjugate vaccine (MCV four) is the only product of its kind in the market, with increasing penetration and registration in Indonesia, marking a significant step in international commercialization [3][4] - The company anticipates the launch of the thirteen-valent pneumococcal conjugate vaccine (PCV13) in 2025, with preparations underway for market-related activities [5] - Other products entering the market include infant DTP (diphtheria, tetanus, pertussis) vaccine, adsorbed tetanus vaccine, and the expansion application for the MCV four vaccine [5] Marketing and Sales Strategy - 康希诺 employs an academic marketing strategy, utilizing a professional team to focus on promotion and implementing a dual-mode approach to drive sales [6] - The company has conducted market segmentation analysis on nearly 10,000 PUCs (Potential User Customers) to develop regional marketing strategies [6] - Plans to expand international business focus on Southeast Asia, the Middle East, North Africa, and South America, with a strong emphasis on clinical registration and commercialization of products like MCV four [7] Future Growth Plans - 康希诺 aims to expand its market share in the 4-6 years, 7-17 years, and 18-59 years age groups, with a focus on newborns for PCV13 and DTP vaccines [8] - The company has a comprehensive product portfolio for bacterial vaccines targeting infants aged 0-6 years and plans to enhance its offerings for older age groups [8] R&D Pipeline and Innovations - The PCV13 vaccine has passed site inspections and is expected to complete production batches by the second quarter of 2025 [9] - The DTP vaccine is prioritized for review due to its excellent phase III clinical data and is expected to be approved by mid-2026 [11] - The company is also developing innovative combination vaccines, including a five-component vaccine, which is currently in the early clinical trial phase [16][19] Challenges and Solutions - The development of meningococcal vaccines faces technical challenges, including immune interference from multiple antigens, which 康希诺 addresses by using different carriers to enhance success rates [20] - The company maintains a low inventory level for its meningococcal vaccine, unaffected by industry-wide destocking trends, and expects further optimization in 2025 [21] Financial Health and Investment Plans - As of December 2024, 康希诺 has approximately 3.5 billion yuan in total funds, indicating a healthy financial status to support R&D and strategic development [22] - The company plans to control capital expenditures and focus on necessary projects, ensuring efficient resource allocation [22] mRNA Technology and Future Directions - 康希诺 is exploring mRNA technology for flu vaccines and has partnered with the Malaysian Institute of Medical Research for multi-valent flu vaccine development [23] - The company has successfully transitioned from the impact of COVID-19 and aims to maximize product value through various collaborations, targeting better performance in 2025 [24]

Financial Performance - Total revenue for the year ended December 31, 2024, was RMB 824,884,000, an increase from RMB 345,182,000 in 2023[10] - Operating loss for the year was RMB (403,390,000), improved from a loss of RMB (2,035,182,000) in 2023[10] - Basic and diluted loss per share for 2024 was RMB (1.53), improved from RMB (6.01) in 2023[10] - The company achieved revenue of approximately RMB 824.9 million during the reporting period, representing a 139.0% increase compared to 2023[62] - Revenue from the cerebrospinal meningitis vaccine product reached RMB 793.8 million, up from RMB 561.7 million in 2023, indicating significant sales growth[63] - The company reported a gross profit of approximately RMB 580.5 million, recovering from a gross loss of RMB 876.0 million in 2023[66] - Other income decreased by 44.5% to approximately RMB 109.5 million, primarily due to a reduction in government subsidies and lower investment returns[67] Assets and Liabilities - Total assets decreased to RMB 7,958,132,000 from RMB 9,318,769,000 in 2023, representing a decline of approximately 14.6%[10] - Total liabilities decreased to RMB 3,048,260,000 from RMB 4,031,354,000 in 2023, a reduction of about 24.4%[10] - Total equity decreased to RMB 4,909,872,000 from RMB 5,287,415,000 in 2023, a decline of approximately 7.1%[10] - Current assets decreased to RMB 4,282,491,000 from RMB 5,180,828,000 in 2023, a reduction of about 17.3%[10] - Non-current assets decreased to RMB 3,675,641,000 from RMB 4,137,941,000 in 2023, a decline of approximately 11.2%[10] Research and Development - The company is focusing on new product development and market expansion strategies to enhance future performance[10] - The product registration application for the innovative 13-valent pneumococcal conjugate vaccine is expected to be submitted in 2024, with the aim of addressing unmet domestic market needs[13] - The recombinant pneumonia protein vaccine has shown promising preliminary results in Phase I clinical trials, covering at least 98% of pneumococcal serotypes[14] - The company is advancing its pipeline of innovative vaccines, including mRNA-based vaccines for influenza and other diseases[22] - The company has received positive results from the Phase I clinical trial of the PBPV vaccine, demonstrating good safety and significant antibody responses in adults and the elderly[35] - The company is developing an innovative tuberculosis booster vaccine, with positive results from Phase I trials indicating good safety and immune response[44] Market Strategy and Expansion - The company aims to establish long-term strategic partnerships based on its diverse product pipeline and is preparing for pre-qualification by the World Health Organization[17] - The product line strategically targets the large and underserved global market, including innovative vaccines and those aimed at replacing existing mainstream vaccines in China[20] - The company aims to expand its international market presence, particularly in Southeast Asia, the Middle East, and Latin America, through strategic acquisitions and partnerships[61] - The company is committed to providing innovative, high-quality, and accessible vaccines to meet global healthcare needs[20] Corporate Governance - The board consists of three executive directors, one non-executive director, and three independent non-executive directors[125] - The company has adopted the corporate governance code as per the Hong Kong Listing Rules Appendix C1, ensuring high standards of corporate governance[123] - The board believes that the current structure, where the chairman also serves as the CEO, benefits the company's operational efficiency[131] - The company will continue to review the effectiveness of its corporate governance structure[132] - The independent non-executive directors are considered independent throughout the reporting period[134] Clinical Trials and Approvals - The company has initiated Phase II/III clinical trials for the Tdcp vaccine for adolescents and adults, addressing a current market gap in China[40] - The company has received clinical trial approval for the DTcP-Hib-MCV4 combined vaccine and aims to meet market demand for combined vaccines[52] - The Phase I clinical trial for the recombinant shingles vaccine officially commenced in Canada in November 2023, with the first subject enrolled[47] - The company has received regulatory approval for its innovative recombinant vaccine products, demonstrating its commitment to research and development[119] Financial Management - Financial income decreased from approximately RMB 563 million for the year ended December 31, 2023, to approximately RMB 222 million for the year ended December 31, 2024, primarily due to a reduction in financial income of approximately RMB 362 million[73] - Income tax expense for the year ended December 31, 2024, was approximately RMB 25 million, a decrease from approximately RMB 115 million in 2023, due to the write-off of deferred tax assets[74] - Cash and cash equivalents decreased by 24.0% from approximately RMB 20,470 million as of December 31, 2023, to approximately RMB 15,565 million as of December 31, 2024, mainly due to cash outflows from operating activities and loan repayments[90] Management and Team - The company has established a strong operational team, significantly contributing to the rapid development and production of COVID-19 vaccines[105] - The management team has extensive experience in the biotechnology industry, contributing to strategic business development[120] - The company has attracted senior professionals from the vaccine industry, enhancing its expertise and capabilities in vaccine development[104] Legal and Compliance - The group faced a lawsuit from Belcher Farmaceutica Ltda. claiming damages of approximately RMB 197 million, but management believes the claim is unlikely to succeed[96] - The company has established written guidelines for employees regarding securities trading to prevent insider trading[124] - The company has implemented anti-corruption policies to enhance daily supervision and prevent unethical business practices[174] Employee Diversity and Inclusion - The company aims to maintain the current female representation on the board, with a long-term goal of achieving gender equality[169] - Among all employees, male employees account for 48.6% and female employees account for 51.4%, indicating a balanced gender diversity within the group[170] - The company will continue to maintain employee gender diversity and has measures in place to enhance gender diversity further[170]

《香港联合交易所有限公司证券上市规则》等相关规定，康希诺生物股份公司（以 下简称"康希诺"或"公司"）于2025年3月25日召开第三届董事会第六次会议， 审议通过《关于提请股东大会授权董事会以简易程序向特定对象发行股票的议 案》，同意公司董事会提请股东大会授权董事会决定公司向特定对象发行融资总 额不超过人民币3亿元且不超过最近一年末净资产20%的股票，授权期限为自公 司2024年年度股东大会审议通过之日起至公司2025年年度股东大会召开之日止。 康希诺: 关于提请股东大会授权董事会以简易程序 向特定对象发行股票的公告 证券代码：688185 证券简称：康希诺 公告编号：2025-009 康希诺生物股份公司 关于提请股东大会授权董事会以简易程序 向特定对象发行股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本次授权事项概述 根据《上市公司证券发行注册管理办法》《上海证券交易所上市公司证券发 行上市审核规则》《上海证券交易所上市公司证券发行与承销业务实施细则》及 本议案尚需提交公司2024年年度股东大会审议通过 ...

康希诺: 2024年度环境、社会及管治（ESG）报告暨可持续发 展报告 关于本报告 本期环境、社会及管治（ESG）暨可持续发展报告本着客观、规范、透明和全面的原则，详细披露了康希诺生物在经营与发 展、环境、劳工与社区、价值链等领域内的 ESG 与可持续发 展的社会责任实践和绩效。 编制依据 汇报原则 本报告依照香港联合交易所有限公司《香港联合交易所有限公司证券上市规则》附录 C2《环 重要性： 为编制本报告，本公司开展议题重要性评估程序，以确定本报告的披露内容及各 境、社会及管治报告守则》及上海证券交易所《上海证券交易所上市公司环境信息披露指 议题内容的 详实程度。2024 年度重大性议题分析结果已呈列在"利益相关方沟通"小节中。 引》要求，参考上海证券交易所《上市公司自律监管指引 第 14 号——可持续发展报告（试 量化：本报告在环境、社会范畴均披露定量数据以展现 我们在各关键 ESG 绩效指标中的 行）》，并参照全球可持续发展标准委员会 (GSSB) 发布的《GRI 可持续发展报告标准》 （GRI 表现。 Standards）要求编写。 报告范围 平衡：本报告客观披露正面及负面信息，确保内容平 衡。 一致 ...

目 录 委托单位： 审计单位： 康希诺: 控股股东、实际控制人及其他关联方资金占 用情况的专项说明 关于康希诺生物股份公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 联系电话： 限公司 总计 3,232.44 49,783.70 64.42 38,172.30 14,908.26 注：该金额已全额计提预期信用损失。 | | | 占用方 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 与上市 | 上市公司 | 2024 年期 | | | 2024 年度 | 2024 | | 年期 | | | | | | | | | | 非经营性资金占 | | 资金占用方 | | | | 占用累计发 | 占用资 | | | 金 | | | 占用形 | | | | | | | | | 公司的 | 核算的会 | 初占用资金 | | | 偿还累计 | | | 发 | 末占用资金 | | 占用性质 | | | | | | | 用 | 名称 | | | | 生金额(不 | 的利 | | | | 息 | | | 成原因 ...